The net sales represented an 11.7 percent increase over the net sales over the same period last year. The net loss for the first quarter was also higher than the same period last year, which was impacted by surgical non-cash items, non-recurring items and other adjustments. The company has provided a valuation allowance against a portion of its deferred tax assets due to the cumulative magnitude of such deferred tax assets.
The company’s surgical implant business segment grew 8.3 percent over the same period last year to $17.8 million. The increase was driven by strong sales in the shoulder products — including the launch of the RSP Monoblock — and hip sales.
More Articles on Orthopedic Devices:
Zimmer’s Q1 Knee & Hip Sales Up 2%, Spine Sales Drop
15 Spine Device Company Leadership Moves
U.S. Minimally Invasive Spine Devices to Top $2.6B by 2018
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
